Richard E. Lowenthal
President and CEO at ARS Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: ARS Pharmaceuticals Inc., 3 years.
ARS Pharmaceuticals Inc.
Director · PRESIDENT AND CEO
Chief executive roles
ARS Pharmaceuticals Inc.
· President and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 17, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −50,000 | $12.93 | $646,500 |
| Sep 17, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −50,000 | $12.93 | $646,500 |
| Sep 10, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −50,000 | $11.50 | $575,000 |
| Sep 10, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −50,000 | $11.50 | $575,000 |
| Aug 20, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −35,944 | $14.76 | $530,533 |
| Aug 20, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −11,756 | $15.61 | $183,511 |
| Aug 20, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −2,300 | $16.26 | $37,398 |
| Aug 20, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −36,216 | $14.76 | $534,548 |
| Aug 20, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −11,523 | $15.62 | $179,989 |
| Aug 20, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −2,261 | $16.25 | $36,741 |
| Aug 13, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −14,599 | $11.78 | $171,976 |
| Aug 13, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −35,401 | $12.76 | $451,717 |
| Aug 13, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −14,637 | $11.77 | $172,277 |
| Aug 13, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −35,363 | $12.77 | $451,586 |
| Jul 16, 2024 | ARS Pharmaceuticals Inc. | Open-market sale | −50,000 | $11.40 | $570,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.